Beyond market trends, investors keen on maximizing returns delve into the world of stock picking. The right selections can be instrumental in catapulting your wealth.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The price of Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) closed at $45.02 in the last session, up 0.69% from day before closing price of $44.71. In other words, the price has increased by $0.69 from its previous closing price. On the day, 0.75 million shares were traded. RARE stock price reached its highest trading level at $46.665 during the session, while it also had its lowest trading level at $44.2.
Ratios:
We take a closer look at RARE’s different ratios to gain a better understanding of the stock. For the most recent quarter (mrq), Quick Ratio is recorded 2.28 and its Current Ratio is at 2.43. In the meantime, Its Debt-to-Equity ratio is 6.65 whereas as Long-Term Debt/Eq ratio is at 6.25.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, Goldman on June 06, 2024, Upgraded its rating to Buy and sets its target price to $67 from $56 previously.
On April 22, 2024, RBC Capital Mkts started tracking the stock assigning a Outperform rating and target price of $77.
On December 08, 2023, Wells Fargo started tracking the stock assigning a Overweight rating and target price of $72.Wells Fargo initiated its Overweight rating on December 08, 2023, with a $72 target price.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Jul 02 ’24 when Sanders Corazon (Corsee) D. sold 584 shares for $40.98 per share. The transaction valued at 23,932 led to the insider holds 12,009 shares of the business.
Parschauer Karah Herdman sold 9,806 shares of RARE for $441,270 on Jun 12 ’24. The EVP and Chief Legal Officer now owns 57,981 shares after completing the transaction at $45.00 per share. On Jun 10 ’24, another insider, Sanders Corazon (Corsee) D., who serves as the Director of the company, sold 1,737 shares for $41.10 each. As a result, the insider received 71,391 and left with 7,248 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, RARE now has a Market Capitalization of 4128532224 and an Enterprise Value of 4234143232. For the stock, the TTM Price-to-Sale (P/S) ratio is 9.21 while its Price-to-Book (P/B) ratio in mrq is 26.67. Its current Enterprise Value per Revenue stands at 9.567 whereas that against EBITDA is -7.687.
Stock Price History:
Over the past 52 weeks, RARE has reached a high of $54.56, while it has fallen to a 52-week low of $31.52. The 50-Day Moving Average of the stock is 7.83%, while the 200-Day Moving Average is calculated to be 4.23%.
Shares Statistics:
According to the various share statistics, RARE traded on average about 877.01K shares per day over the past 3-months and 640830 shares per day over the past 10 days. A total of 90.57M shares are outstanding, with a floating share count of 85.33M. Insiders hold about 5.79% of the company’s shares, while institutions hold 90.02% stake in the company. Shares short for RARE as of 1721001600 were 4362643 with a Short Ratio of 4.97, compared to 1718323200 on 5041498. Therefore, it implies a Short% of Shares Outstanding of 4362643 and a Short% of Float of 5.54.
